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Summary 
• Animal models can support and develop medical product development during the 
nonclinical phase. 
• Well-designed animal models can address regulatory safety concerns and can provide 
further de-risking during product validation. 
• Assessing minimum viable products and prototypes in animal models can improve quality 
assurance and compliance structure. 
• Developing a roadmap for product innovation strategies (regulatory, reimbursement) is 
essential in order to avoid unnecessary preclinical testing. 
• Involving end users in product development is critical for the success of the medical 
device in the market. 
• Animal studies can provide insight and value in the preparation of the regulatory 
submission. 
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Topic Relevance by Timeline 
Summary 
● Animal models can support and develop medical product development during the 
nonclinical phase.  
● Well-designed animal models can address regulatory safety concerns and can provide 
further de-risking during product validation. 
● Assessing minimum viable products and prototypes in animal models can improve quality 
assurance and compliance structure. 
● Developing a roadmap for product innovation strategies (regulatory, reimbursement) is 
essential in order to avoid unnecessary preclinical testing. 
● Involving end users in product development is critical for the success of the medical device 
in the market. 
● Animal studies can provide insight and value in the preparation of the regulatory 
submission. 
Introduction 
The purpose of preclinical animal testing is to provide reasonable evidence prior to early feasibile 
testing in humans and human clinical trials to demonstrate that novel technologies and therapies 
are safe and effective. Contacting prospective end users or Key Opinion Leaders (KOLs) during 
the preclinical phase is critically important and can provide insight and value for the potential 
medical device. It allows to align the technology with the unmet clinical need.  Once an academic 
entrepreneur has focused on the specific problem the product will address, the next step is to define 
the intentional use of the medical device and its indications for use (Speer). The intended use is 
the general purpose of the device (what the academic entrepreneur claims the device actually does); 
the indications for use describe the condition that the device will diagnose, treat, or prevent, as 
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PRECLINICAL ANIMAL MODELS 
well as the target patient population (Speer). The intended use and indications, in essence, describe 
the problem the academic entrepreneur has set out to solve and it must align with an unmet clinical 
need to successfully create value for the medical field downstream (value-based health care sys-
tem). They are important because a key part of the product development process will be dictated 
by how the medical device will be classified by regulatory bodies. That classification is directly 
related to the time and money required to bring the product to market. Furthermore, defining the 
intended use and indications for use will help an academic entrepreneur start to establish the design 
controls and risk management. 
 
Safety and efficacy data from preclinical animal models are an integral part of medical device 
development and necessary to make these decisions. This can help determine if the device is 
effectively solving an actual problem before moving on to costly human trials. Academic centers 
provide unique resources, often housed in the affiliated veterinary medicine schools, that can assist 
academic entrepreneurs in filling this preclinical void. Veterinary medicine schools usually include 
veterinarian faculty and staff with skills in product development for preclinical studies. Veterinar-
ians can assist with a broad range of services, from product development to any regulatory/pivotal 
studies that are needed for good laboratory practice compliance for regulatory filings.  
Elements to Consider for the Animal Study 
In the process of designing preclinical animal research, an academic entrepreneur should provide 
a rationale for the selection of particular animal models for the study. It is important that the 
selected animal model serve as a test platform that offers the best physiological attributes to sim-
ulate the human clinical trials (Table 1). The Food and Drug Association (FDA) recommends that 
the elements of risk analysis and limitations of the animal model be addressed by describing the 
similarities and differences between the selected test platform and humans for utilizing device 
implantation; the surgical technique and location of device insertion in the animal model and in 
humans; and size-appropriate and anatomically appropriate barriers between the animal model and 
humans. 
 
The animal studies for medical devices should be designed to better characterize the likelihood 
that a new therapeutic will be successful and will improve the success rate of clinical trials. An 
academic entrepreneur should conduct preclinical animal testing with the objective of studying the 
risks that are predicted from the design of the device, any known risks of the device type, and any 
new risks that may have emerged in prior investigations. The animal study protocol should reca-
pitulate the human clinical trials as much as possible by encompassing steps from the preparation 
of the device to device placement and all the way to device withdrawal. In addition, medical 
devices can cause mechanical or biological stresses when placed in vivo. Therefore, it is important 
to identify physiological response variables on the body, to improve the chances of success for 
human trials. 
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Table 1. Selection of Biomedical Animal Models. 
 
 
Source: Adapted from Rand; Davidson et al. 
 
During the preclinical development stage, the team should plan to have a pre-Investigational New 
Drug (IND) meeting with the FDA (Center for Drug Evaluation and Research). The goal of a pre-
IND meeting is to receive confirmation from the FDA that the product development plan and future 
clinical trials are acceptable. To make the meeting effective, the team should try to focus on a 
specific regulatory or scientific issue. Pre-IND meetings will provide guidelines for initial IND 
submission at the end of the preclinical development process and can also reduce a product’s time 
to market (see the chapter “FDA Drug Regulation: Investigational New Drug Applications”). 
 
Case study: Intervertebral disk/Nucleus pulposus devices 
For these technologies the 510(k) approval process was often chosen (see the chapter “FDA Device 
Regulation: 510(k), PMA”). Sponsors often had to demonstrate substantial equivalence of their 
product regarding the safety profile using large animal models. Many of these technologies fell 
short demonstrating clinical efficacy in human patients with back pain. One important aspect here 
is to recognize the limitations certain animal models exhibit. For example, large animals do not 
overtly exhibit pain with intervertebral disc degeneration. They may be suitable to study the device 
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in a biological system for tissue compatibility, but fail to address one major clinical metric of 
alleviating pain; which is the single most important driver for clinical outcome in the human 
patient. As a result, the entire field has learned a tremendous amount in the past decade regarding 
intervertebral disc degeneration, pain generators and patient selection. Animal models have also 
become more rigorous. Intervertebral disc degeneration and back pain is a good example to lever-
age naturally occurring disease models that often demonstrate increased rigor and model fidelity 
like for example the dog.     
Minimum Viable Products and Prototypes 
Animal testing using minimum viable products (MVPs) and prototypes are important for develop-
ing medical devices. Product development is comprised of several phases, and each of these phases 
can be considered as an MVP. In the initial phase, an idea or concept can be considered the first 
MVP. The next step is to define the intended use and involve end users; in this scenario, the MVP 
becomes a proof-of-concept prototype (see the chapter “Rapid Prototyping Strategies”). This step 
is essential since it proves invaluable insight into product development efforts. The process con-
tinues, with each MVP evolving as product development progresses toward production; with each 
MVP, it is crucial to include end users to provide feedback. Engaging end users, even in the early 
phases, will help ensure the developed product’s success in the market (see the chapter 
“Conducting Insightful Market Research”). 
 
When going through the phases of evolving MVPs, the FDA recommends that the animal research 
team include skilled veterinary clinical experts in order to detect and resolve adverse outcomes. It 
is also recommended to involve investigators with a range of expertise, including human, clinical, 
and veterinary pathologic fields. Selecting qualified personnel and allocating sufficient resources 
is essential for monitoring and predicting the possible risks of the MVPs.  
Testing MVPs in Animals 
In the development of medical devices, earlier stages usually proceed relatively quickly. However, 
later stages usually require design verification and validation steps, so development slows accord-
ingly. Verification and validation often involve numerous testing activities, and this is a point in 
product development when expenses start to increase exponentially. Therefore, it is important to 
spend a sufficient amount of time defining design inputs in earlier phases since they are the key to 
producing successful MVPs. Also, using prototypes as mini-bench tests to define design inputs 
and to establish verification/validation methods is advantageous. 
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Figure 1. Typical IACUC Review Process.  
 
 
Preclinical animal testing can be done at any of these stages. Consulting with a preclinical testing 
program (e.g., the Institutional Animal Care and Use Committee, IACUC) can be helpful for de-
veloping a regulatory entry strategy (National Research Council (US) Committee for the Update 
of the Guide for the Care and Use of Laboratory Animals; Office of Laboratory Animal Welfare 
(OLAW), National Institutes of Health) (Figure 1); a sample of the University of Pennsylvania’s 
IACUC documents can be viewed here: iacuc.upenn.edu. They may be able to recommend which 
animal to use (e.g., dog vs. sheep vs. pig, etc.; Table 2), which pathological model to use (e.g., 
naturally occurring disease model vs. induced disease model), parameters that need to be consid-
ered (e.g., safety or efficacy, etc.), and how to clarify the budget and milestones in order to satisfy 
regulatory requirements and the goal of the project. They can also be helpful in designing an 
appropriate environment that allows animals sufficient access to food and water, reducing back-
ground stress that could adversely affect the interpretation of study results, and 
observing/monitoring recovery after surgical procedures by providing intensive care treatments 
(e.g., intravenous medications, ECG monitoring, and temperature/humidity adjustments) accord-
ing to regulatory guidelines (National Research Council (US) Committee for the Update of the 
Guide for the Care and Use of Laboratory Animals). 
Design Controls and Risk Management 
In the process of developing MVPs, it is critical to have written documentation of each version. 
This is the essence of risk management and medical device design controls (Speer). In the early 
phases, MVPs guide an academic entrepreneur toward what is important about the product as it 
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relates to end users. Once the academic entrepreneur has a proof-of-concept MVP, they can use 
this to establish and define design inputs. Design inputs are the foundation of the entire product 
development effort, setting the stage for future development activities and directly influencing any 
design verification/testing one plans on performing.  
 
In preclinical animal research, the FDA recommends that the methods and materials utilized for 
the assessment of medical devices be similar to those utilized in humans. It is important to include 
adequate controls to minimize experimental variables and errors. In disease models, background 
levels of disease and psychological stress should be controlled as much as possible to generate 
data that can support the safety and performance of a medical device and obtain predictive out-
comes. In addition, when considering the number of animals needed, it is important to decide 
which disease model to use (e.g., naturally occurring disease model vs. induced or experimental 
disease model). The naturally occurring disease model provides heterogeneity of cohort and 
increased generalizability—allowing for an effective and less expensive study. An induced disease 
model can be more expensive since animals need to be managed in the lab for the duration of the 
experiment. The FDA also recommends that study animals be monitored to assess possible risks 
posed by the device, using a post-mortem evaluations (e.g., micro-CT, light and scanning electron 
microscopy, histopathology). 
 
Table 2. Animal Species Used in Biomedical Research. 
Species Advantages Disadvantages 
Flies  
  
Small, short generation time Not vertebrates 
Fish  
  
Short generation time, clear 
embryos 
Not mammals 
Mice  
  
Mammals, inexpensive, easy to 
handle, relatively small, many 
genetic tools available 
Not primates 
Rats 
 
Same as mice but larger  Fewer genetic tools 
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Rabbits 
 
Nonaggressive, easy to handle, 
widely bred, economical 
compared to other larger animals, 
short vital cycles 
Fragile bone structure, fewer 
genetic tools 
Dogs 
 
Outbred species, large Costly, pets, ethical issues 
Pig/ 
Minipig 
Close analog to humans 
(80-90% of organ system 
corresponds to humans), early 
onset of tumors 
Expensive to procure and 
maintain 
Sheep 
/Goat 
Long life expectancy, 
easy peritoneal catheter insertion, 
 
Difficult and expensive breeding, 
large time frame for obtaining 
results 
Horse Large defects similar to humans, 
naturally occurring defects, 
similar biomechanics, presence of 
melanomas 
Expensive to acquire and 
maintain, difficult to perform 
MRI/CT imaging due to size 
Nonhuman primates 
 
Similar to humans, large Costly, ethical issues 
Source: Adapted from  
http://www.nabr.org/biomedical-research/laboratory-animals/species-in-research/ 
Product Innovation Strategies: Product-Driven vs. Value-
Driven 
There are two popular strategies for product innovation—product-driven and value-driven (Figure 
2). For a product-driven strategy, one identifies the technology first, then assesses it as a solution 
for a problem. In contrast, for a value-driven strategy, one identifies the problem first, then makes 
the technology that serves as the solution. For medical device product development, especially in 
an academic center where a researcher may have done years of work evaluating a specific tech-
nology, the product-driven strategy is a more conventional and traditional approach. End users are 
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involved in this approach, but usually only in the late stages of the product development process. 
This carries significant risks, however, in that the technology may not meet end users’ needs; to 
mitigate this risk, the opinions and feedback of end users evaluating a prototype device are inval-
uable. Therefore, involving end users from the beginning of product development, starting with 
the preclinical phase, can increase the success rate of the product in the market. In part to address 
this issue, value-driven approaches, such as the Stanford Biodesign model, have also been pro-
posed. These can be more challenging for academic researchers, though, as they are often not 
beginning with a technology tabula rasa.  
 
Figure 2. Product-Driven vs. Value-Driven Development Strategies. 
 
PRODUCT-DRIVEN (CONVENTIONAL) STRATEGY: 
 
VALUE-DRIVEN STRATEGY: 
 
 
Case Study: Anti-infective technology 
Involving KOLs (Key Opinion Leaders and clinicians) is important as conventional wisdom about 
diseases and what patients and providers want can often be poorly aligned with the clinical value 
proposition. For example, a polymer carrier matrix impregnated with an antimicrobial was devel-
oped as an anti-infective technology. The development team chose one specific antibiotic as the 
antimicrobial of choice without extensive KOL input which ultimately limited the clinical value 
proposition. However, by the time the product development team had end user feedback, the tech-
nology was too far advanced for them to make adjustments. In general, the business model to bring 
anti-infective technologies to market is broken. The current regulatory landscape requires 
enormous financial investments by product developers including clinical trials. Furthermore reim-
bursement for these clinically unproven technologies can be difficult which further decreases the 
appetite for industry to innovate in this space. This space is a good example to emphasize that 
regulatory clearance is not the only high risk metric in product development and receiving a 
reimbursement code is equally important towards an economically viable product (see the chapter 
“Reimbursement Strategies and CPT Codes for Device Development”).   
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Preparation of Regulatory Submissions 
When preparing regulatory submissions, consider using Europe as an initial market if the FDA’s 
regulatory constraints for the proposed device are significant and make preclinical data challeng-
ing. Starting in Europe is the classical model for many U.S.-based companies, and one could 
present the clinical trial data from use in Europe to support an FDA approval application. In 
Europe, safety data are required, but one does not need to have a large animal study prior to human 
use, unlike in the U.S. Europe is curtailing the use of animals in biomedical research and focusing 
more on safety than efficacy, while in the U.S. efficacy and safety are both key, and a large amount 
of data is required. Another potential option is development in China—this can be easier if working 
with a Chinese partner. Chinese regulatory agencies are also receptive to safety and efficacy data 
collected outside of China. 
 
For regulatory submissions, the FDA recommends including all relevant information collected 
from animal research, not limited to the following: the rationale for the model selection, the simi-
larity of the selected model compared to humans, and the general animal study methodology used. 
In addition, it is important to include the rationale for the transition from the pilot, validation, or 
proof-of-concept studies to pivotal animal studies, as this information provides an understanding 
of how device safety was assessed. If any design changes have been made to the device, they 
should also be described in the regulatory submission, and there should be a performance report 
of the device across multiple studies. 
Conclusion 
Preclinical animal testing is a shared responsibility in which academic researchers, the pharma-
ceutical industry, regulatory authorities, and ethics committees (e.g., IACUCs) all play a part. 
Recently, a number of recommendations and guidelines (see Resources 1 and 4) have been 
published to encourage more accurate use of animal models. Using these guidelines, researchers 
must make sure they are using animals in the best possible way to make progress in the treatment 
of human diseases. Validation is critical for that reassurance, and preclinical animal studies should 
be thoroughly monitored for compliance with these guidelines. This not only limits the mistreat-
ment of animals but also produces consistency and thus increases the potential success rate of the 
medical device in clinical trials as well as in the market.  
Resources 
1. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 
“Product Development Under the Animal Rule.” FDA-2009-D-0007, Food and Drug 
Administration, 6 Oct. 2019, http://www.fda.gov/regulatory-information/search-fda-
guidance-documents/product-development-under-animal-rule. This document provides 
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helpful guidance that explains regulatory considerations, general expectations, and 
essential elements in animal studies.  
2. To get a general overview of preclinical animal research and have a clear understanding 
of pathophysiological differences between animals and humans, refer to the following 
two papers:  
a. Everitt, Jeffrey I. “The Future of Preclinical Animal Models in Pharmaceutical 
Discovery and Development: A Need to Bring in Cerebro to the in Vivo 
Discussions.” Toxicologic Pathology, vol. 43, no. 1, Jan. 2015, pp. 70–77, 3145 
doi: 10.1177/0192623314555162. 
b. Subramani, Baskar, and Sadananda Rao Manjunath. “Preclinical Research: A Rise 
or Dawn.” Pharmacy & Pharmacology International Journal, vol. 6, no. 1, 
MedCrave Publishing, Jan. 2018, pp. 62–65. 
3. Reproducibility and validation of animal models are described in detail in these two 
articles: 
a. Varga, Orsolya E., et al. “Validating Animal Models for Preclinical Research: A 
Scientific and Ethical Discussion.” Alternatives to Laboratory Animals, vol. 38, 
no. 3, June 2010, pp. 245–48, doi: 10.1177/026119291003800309. 
b. Voelkl, Bernhard, et al. “Reproducibility of Preclinical Animal Research 
Improves with Heterogeneity of Study Samples.” PLoS Biology, vol. 16, no. 2, 
Feb. 2018, p. e2003693, doi:10.1371/journal.pbio.2003693. 
4. Center for Devices and Radiological Health. “General Considerations for Animal Studies 
for Cardiovascular Devices—Guidance for Industry and FDA Staff.” Food and Drug 
Administration, July 29, 2010, https://www.fda.gov/regulatory-information/search-fda-
guidance-documents/general-considerations-animal-studies-cardiovascular-devices-
guidance-industry-and-fda-staff.  
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